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Abstract: This study investigates the efficiency of the pharmaceutical industry in Indonesia. The 
data used in this study are secondary data from 2000-2015 obtained from Badan Pusat Statistik. 
The method of study is the quantitative approach to use the Stochastic Frontier Approach. The 
finding results indicated that the pharmaceutical industry in Indonesia during 2000-2015 
technically it has not optimal efficiencies, see from the result of reached an amount of 0.96455986. 
The capital variable has negative and significant effect on the output produced by the producer in 
the pharmaceutical industry, while the labor variable has positive and significant effect on the 
output produced. Limited human resources professionals will make the development of 
innovations to make the pharmaceutical industry as a priority industry in the Industrial Revolution 
4.0 will be inhibited so that the pharmaceutical industry was not achieving optimal efficiency. 
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1. INTRODUCTION 
The industry is supporting economic activities in Indonesia because it provides a useful 
commodity for the community (Bashir, et al., 2019 and Gunadi, 2018). The industrial sector 
became one of the sectors that are large enough to contribute to the economy in the 
amount of 21.22 percent in 2017. Indonesia's economic growth grew by 5.07 percent in 
2017 due to higher growth in the business field. One of them is the manufacturing sector 
that accounted for 0.91 percent. Non-oil processing industry subsectors, one of which has 
the chemical, pharmaceutical, and traditional medicine (Fokunang et al., 2011). This sector 
grew by 4.53 percent in 2017 and the highest growth in Quarter 1-2017 by 8.34 percent. 
However, at the end of 2017, the industry experienced negative growth of 5.46 percent and 
continued to decline until the first quarter of the year 2018 by 6.30 percent. 
Table 1 illustrates that the pharmaceutical industry in Indonesia, more use of imported 
raw materials than traditional medicine industry. More than 80% of pharmaceutical raw 
materials have to be imported. The pharmaceutical industry is also driven by the Ministry 
of Health to be more independent in doing so can suppress the production of drug prices 
and reduce dependence on imported raw materials (Simatupang, 2016) and Kaplan & Laing, 
2005).  
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According to the ministry of industry, restrictions on imports of raw materials 
potentially disruptive to the export-oriented products for the pharmaceutical industry is 
one of the priority industries poised to capitalize on the opportunities of the Industrial 
Revolution 4.0 (Bashir et al., 2019; and Vasin et al., 2018). Security of supply of raw materials 
is one of the important factors in preparing the Industrial Revolution 4.0 that rely on process 
automation and standardization of products (Lavinda, 2018) and Zhong, Xu, Klotz, & 
Newman, 2017), resulting in increasing competitiveness in order to expand market share, 
the company sued the pharmaceutical industry to be more productive and efficient in 
running the company's operations (Hanggraeni, 2011). 
 
Table 1. Use of Raw Materials Industry Import and Local Pharmaceutical Products and 
Traditional Medicines Products Industry 2001-2015 
YEAR Manufacture of Pharmaceutical 
Products 
Traditional Medicinal Products 
Industry 
Imported Raw 
Materials 
Local Raw 
Materials 
ImportedRaw 
Materials 
Local Raw 
Materials 
% % % % 
2001 64.80 35.20 5.29 94.71 
2002 52.75 47.25 20.25 79.75 
2003 53.92 46.08 0.99 99.01 
2004 57.27 42.73 0.69 99.31 
2005 53.18 46.82 3.36 96.64 
2006 64.47 35.53 7.23 92.77 
2007 64.75 35.25 0.76 99.24 
2008 93.86 6,14 0.18 99.82 
2009 92.27 7.73 0.83 99.17 
2010 84.97 15.03 2.43 97.57 
2011 83.01 16.99 5.95 94.05 
2012 48.82 51.18 2.43 97.57 
2013 53.25 46.75 1.37 98.63 
2014 53.86 46.14 21.79 78.21 
2015 46.15 53.85 82.86 17.14 
Total 80.8% 19.2% 10.3% 89.68% 
Source: The Central Bureau of Statistics (Author’s processed, 2019) 
 
2. LITERATURE REVIEW 
Approach Structure Conduct Performance (SCP) which was built by a Harvard 
economist, namely Edward S. Mason (1949) and colleagues Joe. S. Basin (1959) found a 
strong correlation between an industry market structure, business practices and behavior 
of the parties forming the market and the performance of the industry itself (Janah, 2008). 
Edward S. Masson (1988) in Ward (2008) states that there is a fairly high rise in the market, 
it must look at the performance of the market first. Outreville (2014) said performance can 
be seen from the behavior that reflected the market structure. So the performance of a 
company can be seen from the structure of the market that will affect the behavior of the 
market. 
According to Prajanti and Setiawan (2011) explains that the production function is 
defined as a technical relationship between inputs to outputs, which this relationship shows 
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the output as a function of the symbolic input. The production function can be written as 
follows:  
Q = f (X1, X2, X3, ...... Xn) 
Where: Q is output, X1 ... Xn is various inputs that contribute to generate the Q output 
capable inputs used in the production process there are relatively fixed inputs and variable 
input. Inputs used in the production process, among others, capital, labor, dummy, and 
others. In economics, the output is denoted by Q, while inputs (factors) that are used 
typically (for simplicity) consist of capital input (K) and labor (L). 
The production function Cobb-Douglas exponential or is already widely used in studies 
of the empirical production function, especially since Charles W.Cobb and Paul H. Douglas 
started using it at the end of 1920. This function or equation involves two or more variables, 
which one variable called the dependent variable or explained (dependent variable), and 
the other is called the independent variable or explain variable (Cobb and Douglas, 2010). 
Mathematically, Cobb-Douglas production function can be written as follows: 
𝐹(𝐾, 𝐿) =  𝐴𝐾𝛼𝐿𝛽 
Where: A = Productivity; K = Capital; L = Labor; and α and β = output elasticity of labor and 
capital. Where A, α, and β are positive constants. When the Cobb-Douglas function is 
expressed in relation between X and Y, it can be written: 
𝑌 = 𝑓(𝑋1,, 𝑋2 … , 𝑋𝑛) 
For simplicity, this equation is transformed into a linear form, namely: 
𝑙𝑛𝑌 = 𝑙𝑛𝑎 + 𝑏1𝑙𝑛𝑋1 + 𝑏2𝑙𝑛𝑋2 + ⋯ + 𝑏𝑛𝑙𝑛𝑋𝑛 + 𝑒 
Agner and Chu (2006) developed a deterministic parametric frontier approach through the 
specification of homogeneous frontier production function Cobb-Douglas that require all 
observations are at or below the frontier. The model can be written as follows(Coelli et al., 
2005). 
𝑙𝑛𝑞𝑖 =  𝑥𝑖
′𝛽 − 𝑢𝑖  
Where: q1 represents the output of the i is the firms; Xi is a K × 1 vector containing the 
logarithm of the input; β is the unknown parameter vector and ui is a non-negative random 
variable associated with technical inefficiency. Β parameter vector elements obtained by 
linear or quadratic programs. 
Nicholson (2002) explains that efficiency is the ability to achieve the expected results 
(output) at the expense of (input) is minimal. An activity is said to be efficient if the activities 
have reached the target (output) to sacrifice (input), the lowest, so no waste. Efficiency is 
the ratio of the value added generated an industry with the inputs used in the form of labor, 
raw materials, capital, and others(Lieberman & Kang, 2008).  Efficiency cannot be separated 
from the allocation of inputs in the production. Production will be efficient if economically 
at a level output when no other process that can produce a similar output with lower cost 
(Hasibuan, 1993). 
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3. MATERIALS AND METHODS 
This study used secondary data of pharmaceutical products industry (ISIC code 21012) 
in Indonesia from 2000 to 2015 were obtained from the Central Bureau statistically. The 
data used is the data of capital and labor in the pharmaceutical industry from 2000 to the 
2015. This study uses the quantity of technical analysis is Stochastic Frontier Deterministic 
Parametric through frontier production function specification homogeneous Cobb Douglass 
requiring all observations under the frontier. The model can be written as follows (Coelli et 
al., 2005): 
ln 𝑞𝑖 =  𝑥𝑖𝛽 − 𝑢𝑖 
Where: q represents the company to the output-1, xi is the logarithm vector output, ß is the 
vector of unknown parameters and ui is a non-negative random variable associated with 
technical inefficiency. Ss parameter vector elements obtained by the linear or quadratic 
program. 
Stochastic Frontier Approach used to estimate the Cobb Douglas production function 
using panel data on a parametric approach Stochastic Frontier with the following functions: 
𝑌 =  𝛽0𝑋1. 𝛽1𝑋2. 𝛽2𝑋3𝑒
𝑢 
Is transformed into a linear form of logarithms with the following functions: 
 
𝑙𝑛𝑂𝑖 = ln 𝛽0 + 𝛽1𝑙𝑛𝐾𝑖 + 𝛽2𝐿𝑖 + 𝑣𝑖 − 𝑢𝑖 
Where: Y = Output; K1 = fixed capital; L2 = the number of workers ß0 = intercept; ß1 = 
coefficient of parameter estimators where I = 1,2, ....; and vi- u = is the error term (Effect of 
technical inefficiency in the model). Coefficient values expected: ß1, SS2,> 0, meaning that 
the results of Stochastic Frontier estimate a production function above is expected to give 
a positive value estimated parameters. 
Technical efficiency value can be determined from the data with Frontier Software 
Version 4.1c. If the value of technical efficiency that has been processed using a Stochastic 
Frontier nearing the added value and the cost of associate use and equal to one (= 1) then 
it is efficient, whereas when the value of technical efficiency of less than one, then the 
inputs used are inefficient. 
Maximum likelihood estimation was better than Ordinary Least Square Estimation. This 
is caused by maximum likelihood estimation is able to describe the real state of the 
population in the form of the average value of samples or any other value that is best able 
to show the state of the sample, while the Ordinary Least Square Estimation only able to 
describe the real state of the population in the form of the average value of the sample. A 
variety of tests necessary to ensure the model specification. The test includes testing the 
existence of a standard deviation for maximization or minimization or test sigma-squared 
(σ2), test the accuracy of the model maximum likelihood estimation or test gamma (γ), test 
the effect of inefficiency in the model or z test, a technical test comparison of models or 
test LR ( λ) and the independent variable significance test or t-test.  
Sigma squared test (σ2) is a statistical value calculation used to determine how the 
distribution of data in the sample, and how close individual data to the mean or average 
value of the sample. Criteria for acceptance of the null hypothesis (Ho) t <t table and 
acceptance criteria Ha namely t> t table. While, Gamma test is one of the associative non-
parametric test. Gamma measures the relationship between two variables ordinal scale that 
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can form into a contingency table. This test is to measure the relationship that is 
symmetrical meaning that variable A and variable B can be mutually correlated. 
 The null hypothesis (H0): γ = 0: The model to be used is OLS model 
 The alternative hypothesis (Ha): γ ≠ 0: The model to be used is a model MLE (maximum 
likelihood estimation). 
 
Acceptance criteria for the null hypothesis (H0) t-test < t-table and acceptance criteria 
Ha namely t-test > t-table. 
The Z-test is a statistical test using normal distribution approach. Z test can be used to 
test large-sized sample data. Tests on the presence or absence until inefficiency did use z-
test, where the test criteria of this test are to compare the counted value with a z z table. 
Here's the formula used to calculate the value of z is calculated. 
𝑍 =
𝜆
𝑠𝑒(𝜆)
 
Where: λ is the coefficient of the variable λ (gamma) produced and estimated production 
function model; se(λ) is the standard error of λ which is also produced from production 
function model estimation. The preparation of the hypothesis of the Z test is as follows: 
 Ho λ = 0: no influence inefficiency or fully efficient output 
 Ha λ = 0: No effect on output inefficiency 
Criteria arithmetic test if the value of z> z table then Ho is rejected, it means that there 
are significant inefficiencies in the production process. 
 
4. RESULTS AND DISCUSSION 
The following is the value added of the pharmaceutical industry in Indonesia during 
2000-2015. Value added is obtained from the difference in the value of output produced 
during production and the costs incurred to produce (intermediate costs). 
 
Figure 1. The Added Value of the Pharmaceutical Industry in Indonesia 
Source: Badan Pusat Statistik (Author’s processed, 2019) 
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Based on the Figure 1, it can be seen that the value added of the pharmaceutical 
industry is always higher than the middle costs incurred except in 2001 and 2009. Added 
value in 2009 was the highest added value during of 2000-2015. However, the intermediate 
costs incurred in that year were greater than the value added generated. This was due to 
the high use of raw materials used for production despite the increased output. 
 
 
Figure 2. The Efficiency of Pharmaceutical Industry in Indonesia, 2000-2015  
Source: Badan Pusat Statistik (Author’s processed, 2019)  
 
Efficiency measurement is used to see the performance of an industry based on the 
costs incurred during the production process and the value added generated. The 
development of the level of efficiency of the pharmaceutical industry is determined by the 
comparison of the added value generated with the intermediate costs incurred during the 
production process. The following is general efficiency of the pharmaceutical industry 
during 2000-2015. 
Although the highest value added of the pharmaceutical industry occurred in 2009, the 
most optimal efficiency during of 2000-2015 was in 2014. This was caused by the value 
added generated higher than the value of input/intermediate costs incurred during the 
production process. While the lowest efficiency values occurred in 2001 is 0.88. This is 
because the use of intermediate costs during the production process is quite high but does 
not increase output or the added value generated. 
Table 2 show that the capital variable (K) has a coefficient of -2.0616647. This means 
that if the use of capital variable increases by one percent it will reduce output by 2.0616647 
percent. The intended capital is depreciation of fixed capital. While, labor variable (L) has a 
coefficient of 1.23958. This means that if the use of labor variables increase by one percent 
it will increase output by 1.23958 percent.  
The t-test is used to see the significance of the influence of the independent variable on 
the dependent variable. The significance of this influence can be estimated by comparing 
the value of t-count with t-table at α = 5 percent and degree of freedom (df) 14 which is 
1.7613. Based on the estimation it can be concluded that the capital variable has negative 
and significant effect on output can be seen from the value of t-test < t-table (-5.153764 < 
1.7613). This also means that capital has a negative influence on the output produced. The 
labor variables has positive and significant effect on the output of the Indonesian 
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pharmaceutical industry. This can be seen through the value of t-ratio > t-table 2.698 > 
1.761. This means labor has a positive relationship with output. The greater labor force 
expended, the ability of the pharmaceutical industry to produce output is also greater. The 
model estimation results, technical efficiency using the Stochastic Frontier Production 
Function are as follows: 
 
Table 2. Estimation Results of Frontier Production Functions 
Variable 
MLE (Maximum Likelihood Estimation) 
Coefficient Standard-Error t-ratio 
Constant 460.08362 1.0000864 460.04385 
Ln K -2.0616647 0.40003084 -5.153764 
Ln L 1.2395802 0.45944317 2.6980055 
Sigma-squared (s) 49.733125 17.320352 2.8713692 
Gamma (γ) 0.00004198 0.024549 0.0017101841 
Log like-hood function = -0.53956369 
Mean eff. in year = 0.96455986 
Level significant = 5 % 
t-table (5%, 14) = 1.7613 
t-table (1%, 14) = 2.624 
Source: Author’s use Stochastic Frontier Approach (2019) 
Simply rewritten as follows: 
𝑙𝑛𝑌𝑖𝑡 = ln 460.08362 − 2.0616647𝑙𝑛𝐾𝑖𝑡 +  1.239580𝑙𝑛𝐿2 
The efficiency in this study can compare the gamma coefficient with the standard 
gamma error. 𝑧 =  𝐺𝑎𝑚𝑚𝑎/(𝑠𝑒. 𝑔𝑎𝑚𝑚𝑎) The calculated z value is 0.0000419847/ 
0.024549818 = 0.00171018376. The calculated z value is 0.001710183 percent of the output 
produced. In this case, the hypothesis is accepted, the production output is not fully 
efficient. The result of the calculation of technical efficiency in mind the use of capital and 
labor as inputs Indonesian pharmaceutical industry has already reached efficiencies 
technically though not optimal.  
Based on estimates obtained the highest technical efficiency occurred in 2009 which 
amounted to 0.9648 or nearing one and 2004 is the year in which the technical efficiency of 
the lowest in the pharmaceutical industry. It can be seen from the picture above that 2004 
closest to the center point of the image. The average efficiency of the pharmaceutical 
industry is equal to 0.96455986 of a frontier or maximum production, i.e. less than 1. This 
means that the use of factors of production is not technically efficient. This is in line with 
research from Fazri et al. (2017) argue that most of the processing industry in Indonesia 
increased efficiency unless the timber industry. 
Overall the pharmaceutical industry in Indonesia has a high efficiency although not 
optimal. If the pharmaceutical industry wants to achieve maximum efficiency, the 
pharmaceutical industry must increase its output only amounted to 3,544 using the same 
input. The cause of the pharmaceutical industry has not yet reached the optimal technical 
efficient due to the raw materials used in the production process using more than 80.00 
percent of imported raw materials. The use of high import raw materials caused by the 
production of local raw materials has not been going well. This is because the raw materials 
of the pharmaceutical industry in the country are still not able to provide the basic materials 
needed by the pharmaceutical industry in terms of both types, supply, and price 
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competitive. If the raw materials are not available in the country, the pharmaceutical 
manufacturers have to import raw materials or intermediate materials from abroad, so it is 
done in the country only a final stage of the formation of raw materials. This can lead to 
greater production costs which impact inefficiency to the pharmaceutical industry and also 
lead to dependence on imported raw materials and prone to fluctuating currency exchange 
rates. 
 
 
Figure 3. Technical Efficiency in Pharmaceutical Industry 
Source: Stochastic Frontier (Author’s processed, 2019) 
Constraints on imported raw materials above are not produced in the country is better 
utilization of natural resources of plants, animals, minerals and mineral and gas is still 
limited. Not only that, the lack of research for innovation and technology transfer also 
provide obstacles for Indonesia to produce pharmaceutical raw materials. 
 
5. CONCLUSION 
The pharmaceutical industry in Indonesia in 2000-2015 are technically not achieving 
optimal efficiency (0.9646). This is due to the pharmaceutical industry uses imported raw 
materials more than 80 percent of the production process. The low quality of labor in 
Indonesia least impact on the performance of the pharmaceutical industry. Limited human 
resources professionals will make the development of innovations to make the 
pharmaceutical industry as a priority industry in the Industrial Revolution 4.0 will be 
inhibited so that the pharmaceutical industry was not achieving optimal efficiency. 
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